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Abstract
The relative ability of IgG subclasses to cause acute inflammation, and the roles of specific
effector mechanisms in this process is not clear. We explored this in an in vivo model of
glomerular inflammation in the mouse. TNP was planted on the glomerular basement membrane
after conjugation to nephrotoxic antibody. The relative nephritogenicity of anti-TNP switch-
variant monoclonal antibodies was then explored and shown to be IgG2a>IgG2b, with no disease
caused by IgG1. Using knockout mice, we showed that FcγRIII was necessary for both neutrophil
influx and glomerular damage induced by IgG2a and IgG2b. Surprisingly IgG1 did not cause
disease although it binds to FcγRIII. Using blocking antibodies, we showed that this was
explained by an additional requirement for FcγRIV which does not bind to IgG1. IgG2a or IgG2b
induced neutrophil influx was not affected by deficiency of either FcγRI or C3. Bone marrow
chimeras were constructed to test the effect of combined deficiency of FcγRI and C3, and there
was no effect on IgG2a or IgG2b mediated neutrophil influx. However, IgG2b-induced
albuminuria and thrombosis was reduced in C3 deficient mice, showing an additional role for
complement in IgG2b-mediated glomerular damage. The results show that IgG2a and IgG2b are
the pathogenic subclasses in acute neutrophil-mediated glomerular inflammation, with an
indispensible role for both FcγRIII and FcγRIV. In addition complement contributes to IgG2b
induced glomerular injury.
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Introduction
Several lines of evidence support a central pathogenic role for immune complexes in
systemic autoimmune disease such as systemic lupus erythematosus, rheumatoid arthritis
and vasculitis. Many of these systemic diseases have glomerulonephritis as their most
serious manifestation, and in addition immune complexes play a role in other forms of
primary GN3. Although the relative roles of cell-mediated and humoral immunity in
glomerulonephritis continue to be debated, some key observations show a crucial role for
immune complexes. Lupus-prone mice deficient in Fc receptors are almost completely
protected from glomeruonephritis, despite the deposition of immune complexes (1). Fc
receptor-deficient mice are also protected from autologous nephrotoxic nephritis (2). The
latter is an induced model of glomerulonephritis in which disease is caused by an autologous
response to a foreign antibody planted on the glomerular basement membrane.
The proinflammatory functions of IgG are largely determined by the interaction of the Fc
portion of the heavy chain with complement and with Fc receptors. Murine IgG subclasses
differ in their ability to activate complement, with IgG2a, IgG2b, but not IgG1 activating
complement well (3, 4). Cell membrane receptors for the Fc portion of IgG are widely
distributed on macrophages, monocytes, neutrophils, and couple immune complex formation
to cellular effector mechanisms (5). Activating Fc receptors comprise FcγRI, FcγRIII and
the recently described FcγRIV (6). FcγRI is a high affinity receptor that has been shown in
vitro to bind monomeric and complexed IgG2a, with a much lower affinity for IgG2b (7).
FcγRIII is a low affinity receptor that binds to IgG2a, IgG1 and IgG2b but not IgG3 (8).
FcγRIV binds to IgG2a and IgG2b with little affinity for IgG1 and IgG3 (6).
Particular forms of GN are associated with specific subclasses of IgG in both men and in
mice. Human lupus nephritis has been associated with IgG1, 2 and 3, membranous
nephropathy with IgG4, mesangiocapillary GN with IgG3, and anti-GBM disease with IgG1
and IgG4 (9-11). In murine lupus, earlier studies suggested that IgG2a was the dominant
subclass in glomerular eluates from NZB/W mice (12, 13). In BXSB mice IgG2b was
reported be the dominant subclass in glomerular eluates, with IgG2a and IgG2b equally
common in MRL/lpr mice (13). A recent report in spontaneous lupus-like disease, in mice
lacking the inhibitory receptor FcγRIIb, has also suggested that IgG2a and IgG2b are the
dominant subclasses deposited in glomeruli (14). The descriptive finding of particular IgG
subclasses in serum, on immunfluorescence staining or in glomerular eluates does not
directly demonstrate the pathogenicity of these subclasses. It is quite possible that a subclass
deposited in small amounts is highly pathogenic. In addition the relative amounts in serum
or glomeruli are difficult to judge in assays that use subclass specific detecting antibodies
that have different affinities. In order to directly show the effect of an IgG subclass, the
antibody needs to be passively given in vivo in a model of inflammation. Even then, the
relative role of IgG subclasses cannot be reliably deduced from studies that compare random
panels of monoclonal antibodies. A previous study in rats compared disease that was
induced by monoclonal antibodies to type IV collagen in WKY rats (15). However, as well
as being of different subclasses, these monoclonal antibodies would have differed in affinity
and specificity and this could have lead to differences in pathogenicity. The most rigorous
way to assess the role of subclass is through the use of switch variants that have identical
heavy and light chain variable regions, and differ only in the heavy chain portion
determining subclass.
3Glomerulonephritis
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Previous in vivo studies have explored the role of IgG subclass using switch variants in
models such as haemolytic anaemia (16), melanoma therapy and thrombocytopenia (6, 17),
and lymphoma treatment (18). In order to assess the role of IgG subclass in acute glomerular
inflammation we have developed a model in which disease is passively induced by
monoclonal switch variants against trinitrophenol (TNP), after TNP was first planted on the
glomerular basement-membrane. We could show that even a high dose IgG1 was unable to
induce disease, whereas lower doses of IgG2a and IgG2b were pathogenic, with more severe
disease caused by IgG2a. Using knockout mice and blocking antibodies, we explored the
effector mechanisms responsible. Our data show that both FcγRIII and FcγRIV were
required for all of the disease manifestations caused by IgG2a and IgG2b. In addition,
complement contributed to IgG2b-mediated glomerular damage, as reflected by the
development of thrombosis and proteinuria.
Materials and Methods
Mice
FcγRI and FcγRIII deficient mice were generated as described (19, 20). FcγRI deficient
mice were backcrossed 6 generations onto a C57BL/6 background (from a mixed C57BL/6/
BALBc/129 background), and FcγRIII deficient mice were backcrossed 12 generations onto
C57BL/6. C3 deficient mice were originally obtained from M Carroll (21) and backcrossed
11 generations onto C57BL/6. Wildtype C57BL/6 mice were obtained from Harlan, UK.
Bone marrow chimeras were constructed as described previously (22). Chimerism was
assessed as described using real-time PCR for the neomycin resistance gene (present in
C3-/- but not FcγRI-/- mice) on genomic DNA from peripheral blood as described (22). C3
levels were measured in the serum of FcγRI-/-→ C3-/- chimeras by ELISA. The coating
antibody was sheep anti-mouse C3 (ICN Biomedicals) and the detecting antibody HRP-
conjugated goat anti-mouse C3 (Nordic). The standard was serial dilutions of normal mouse
serum. Age, sex and weight matched mice were used for all experiments. All experiments
were performed according to UK home office regulations.
Monoclonal anti-TNP switch variant and anti-FcγRIV antibodies
Hybridomas secreting IgG1, IgG2a and IgG2b anti-TNP switch variants were a gift from
Lucien Aarden (Sanquin, Amsterdam). An IgG1 hybridoma Hy2.15 derived from BALBc
mice was originally a gift from George Kohler. The switch variants were obtained from this
hybridoma by sequential sublining in combination with isotype-specific ELISAs according
to previously published methods (23). Anti-TNP hybridomas were grown at standard cell
density in serum free medium, and purified using protein G chromatography from
concentrated supernatant under identical conditions. Purity was confirmed at greater than
95% by SDS gel electrophoresis. After purification, the affinity of the monoclonal
antibodies were compared by ELISA. Maxisorb ELISA (Nunc) plates were coated with
Trinitrophenol conjugated sheep IgG (prepared as below) at 10μg/ml. After blocking with
1% BSA, various dilutions of monoclonal anti-TNP were applied. The detecting antibody
was alkaline phosphatase conjugated polyclonal anti-kappa light chain (Southern Biotech).
FcγRIV receptor-blocking antibody 9E9 has been described previously (6) and was purified
with protein G chromatography. Flow cytometric analysis 9E9 specificity was performed as
described (6). Normal hamster IgG (Jackson’s Immunoresearch) was used as a control.
Induction of glomerulonephritis
Nephrotoxic antibody was prepared by immunising sheep with a kidney extract prepared as
previous described (24). IgG was purified using DEAE sepharose, and was more than 90%
pure on SDS gel electrophoresis. This was conjugated with TNP by incubation with
trinitrofluorobenzene in 0.2 M Bicarbonate buffer pH9. After dialysis into PBS, the
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conjugate was characterised spectrophotometrically using a described formula (25).
Conjugates used had a ratio of 11 moles TNP per mole of IgG. Disease was induced by
injecting 1.3 mg of conjugate intravenously, followed 24 hours later by anti-TNP
monoclonal antibody. LPS was from Escherichia coli 0111:B4 (Sigma, catalogue number
L3024).
Assessment of disease severity
Kidney was fixed in Bouin’s solution, and paraffin embedded sections stained with periodic
acid-Schiff. Neutrophils were counted and thrombosis scored as described (22, 26). Urine
was collected from mice that were housed in metabolic cages for 24 hours immediately
following the injection of monoclonal antibody, and albuminuria was measured by radial
immunodiffusion as described (22) The sensitivity of the assay was 25μg/ml. Peripheral
blood neutrophil numbers were measured as described (22).
Immunofluorescence staining
This was performed on material snap-frozen in isopentane. Direct immunofluorescence for
TNP was performed using the IgG1 monoclonal anti-TNP, conjugated with FITC using
standard techniques. Indirect immunofluorescence for complement components was
performed using rat monoclonal anti C1q, C3 or C4 (all from Cedar lane), and FITC mouse
anti-rat IgG (Jacksons Immunoresearch). For assessment of complement staining, image
analysis techniques could not be used due to the mesangial deposition of complement seen
in normal mice. The basement membrane staining was therefore assessed by the observer
(with no knowledge if sample identity) on a scale 0-4, disregarding the mesangial staining.
For FcγRIV staining, 9E9 was used with detection by goat anti-hamster IgG (Jacksons
Immunoresearch), followed by Alexa fluor 488 goat anti-FITC (Molecular Probes).
Statistics
Statistics were performed using Graphpad Prism (Graphpad Software). A student’s t test was
used where two groups were compared and a one-way ANOVA with either Tukey’s or
Dunnett’s post-test where there were more than two groups. Data were analysed after a
logarithmic transformation if the variances were significantly different.
Results
Induction of glomerular inflammation by monoclonal anti-TNP antibody
We first established a model in which glomerular inflammation was induced by anti-TNP
monoclonal antibody. TNP-conjugated nephrotoxic antibody was injected, followed 24
hours later by monoclonal anti-TNP antibody. Immunofluorescence staining verified that
TNP was deposited on the glomerular basement membrane, along with mouse IgG, as
shown in figure 1A and B. Preliminary experiments established that endotoxin was
necessary as a co-factor, and that 15mg/kg of IgG2a was needed to cause robust disease.
When 100ng of endotoxin was given with 15mg/kg IgG2a anti-TNP monoclonal as a single
intravenous injection, a significant neutrophil influx was seen, as shown in figure 1C. When
either monoclonal antibody or endotoxin alone was given, only a mild neutrophil influx was
seen, as shown in Figure 1D. These results established a requirement for endotoxin, and this
was given with monoclonal antibody at a dose of 100ng per mouse in all subsequent
experiments. As we planned to compare disease induced by the switch variants, it was
important to verify identical binding to TNP of purified antibody. This was confirmed by
ELISA as shown in figure 1E.
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Relative pathogenicity of switch variant monoclonal antibodies
As we had established that 15mg/kg of IgG2a was necessary in order to induce disease, we
compared disease induced by this dose of IgG1, IgG2a and IgG2b anti-TNP switch variants.
Results at 2 hours are shown in figure 2A, with representative histology in figure 3. IgG2a
induced a greater neutrophil influx into glomeruli than IgG2b or IgG1. IgG2b induced a
greater neutrophil influx into glomeruli than IgG1. IgG1 did not cause a neutrophil influx,
since neutrophil numbers in glomeruli after IgG1 administration were not significantly
different to those seen after endotoxin alone. Note that in this and later experiments, the
control group given endotoxin alone were given TNP-conjugated nephrotoxic antibody 24
hours earlier, as were the other mice. We then assessed whether a higher dose of IgG1 could
induce a neutrophil influx. Even 100mg/kg of IgG1 did not result in a neutrophil influx
greater than that seen after endotoxin alone. IgG2a induced more severe albuminuria than
IgG2b as shown in figure 2B. Even after 100mg/kg of IgG1, albuminuria was seen only at
trace levels (< 70μ□/24 hours in all mice). At 24 hours, assessment of glomerular
thrombosis gave results that mirrored those for albuminuria as shown in figure 2B with
representative histology in figure 3. There was significantly more thrombosis after IgG2a
than IgG2b with none seen even after 100mg/kg of IgG1. These data established the relative
pathogenicity of IgG subclasses as IgG2a > IgG2b ≫ IgG1.
Complement activation in vivo due to switch variant monoclonal antibodies
In order to assess the relative ability of the switch variants to activate complement we
stained kidney sections for C1q, C4 and C3. This was performed on samples from the
experiment shown in figure 2A in which 15mg/kg of IgG1, IgG2a or IgG2b had been given.
C1q was detected in a linear pattern on the glomerular capillary wall after IgG2a and IgG2b
but not after IgG1. In mice that were given endotoxin alone and no monoclonal antibody,
faint mesangial C3, and strong mesangial C4 staining was seen, at similar levels to those
seen in untreated mice. However, superimposed on this pattern, there was linear capillary
wall staining after IgG2a and IgG2b but not after IgG1. Capillary wall staining for both C3
and C4 was stronger for IgG2b than for IgG2a. Representative glomeruli are shown in figure
4A and data in figure 4B. These data established that IgG2b was a stronger activator of the
classical pathway than IgG2a, with no activation by IgG1. They also established that IgG1
did not bind C1q.
Effector mechanisms causing IgG2a and IgG2b mediated disease
We then proceeded to explore the effector mechanisms responsible for disease induced by
IgG2a and IgG2b using knockout mice. We compared disease induced by 15mg/kg IgG2a or
IgG2b in wildtype mice with that seen in FcγRI, FcγRIII and C3 deficient mice. Figures 5A
and 6A show that FcγRIII is absolutely required for the neutrophil influx due to IgG2a and
IgG2b respectively. In the absence of FcγRIII, neutrophil numbers were the same as those
seen after endotoxin alone in both cases. We did not demonstrate any role for FcγRI or
complement in the neutrophil influx due to either IgG2a or IgG2b, as neutrophil numbers in
FcγRI and C3-deficient mice were equivalent to those seen in wild type mice in both cases.
As shown in figure 5B, albuminuria due to IgG2a was significantly decreased in FcγRIII
deficient mice but not in C3 deficient mice compared to wildtype controls. However IgG2b
induced significantly less albuminuria in both FcγRIII and C3 deficient mice than in
wildtype controls, as shown in figure 6B. The results for glomerular thrombosis mirrored
these data as shown in figure 5C and 6C. These data established that FcγRIII, but not FcγRI
or C3, was indispensable for the glomerular neutrophil influx due to either IgG2a or IgG2b.
However glomerular damage (as shown by thrombosis and albuminuria) due to either IgG2a
or IgG2b depended on interaction with FcγRIII with an additional role for complement in
the case of IgG2b but not IgG2a.
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FcγRIV is also required with no role for combined C3 and FcγRI deficiency
Our experiments so far had shown that IgG2a and IgG2b but not IgG1 was pathogenic with
a dominant role for FcγRIII. This presented a paradox since IgG1 is known to interact with
FcγRIII. It remained possible that FcγRI and C3 were important for the neutrophil influx in
IgG2a and IgG2b-mediated disease, but that this was not apparent in mice deficient in only
one of these molecules. In order to explore the effect of a combined deficiency, we
generated bone marrow chimeras by transplanting FcγRI deficient marrow into C3 deficient
mice. These animals lacked FcγRI on neutrophils, and circulating C3. Analysis of genomic
DNA from peripheral blood in 8 chimeric mice showed 94.89±5.11 % donor-derived bone
marrow cells. We confirmed that circulating levels of C3 were less than 1% of those found
in wildtype mice in all 7 chimeras tested. These animals were compared with sham chimeric
mice (wildtype donor and recipient). As shown in figure 7, there were no differences in
neutrophil numbers when disease was induced by 15mg/kg IgG2a or IgG2b (with
endotoxin) in these mice. These data established that FcγRI and C3 did not play a role in the
neutrophil influx in this model, even in mice rendered doubly deficient. A further possible
explanation for the lack of a pathogenic role of IgG1 is that the development of disease
requires not only activation of FcγRIII but also of the recently described FcγRIV which
does not bind IgG1. In order to explore this we used the blocking monoclonal antibody 9E9.
A previous publication has shown specificity data for another monoclonal 9G8.1 (6), and in
figure 8A we show similar data for 9E9. Data showing that cells expressed the relevant
transfected Fc receptor in these experiments is in this previous publication (figure 2B). We
also performed immunofluorescence staining using 9E9. As shown in figure 8B, this
confirmed that FcγRIV was expressed in glomeruli of mice with disease and a glomerular
neutrophil influx, but not in glomeruli from normal mice. FcγRIV was also expressed in the
intersitium but this was also present in normal mice and probably represents resident
dendritic cells or macrophages.
We performed experiments in which 20mg/kg FcγRIV blocking antibody or control was
given to mice 90 minutes before disease induction. As shown in figure 9A and 9B, there
were significantly less neutrophils infiltrating glomeruli after FcγRIV blockade in both
IgG2a and IgG2b-mediated disease. Levels were similar to those seen after endotoxin alone
(with mice given TNP-conjugated nephrotoxic antibody, then control hamster IgG, followed
by endotoxin alone in this control group). Albuminuria (figure 9C and 9D) and thrombosis
(figure 9E and 9F) were also significantly decreased after FcγRIV blockade. These data
established that, in addition to FcγRIII, FcγRIV was required for both glomerular
neutrophil influx and glomerular damage in both IgG2a and IgG2b mediated disease.
Peripheral blood neutrophils are similar in all groups of mice
It was possible that differences in glomerular neutrophil numbers simply reflected
differences in peripheral blood neutrophils. To explore this possibility, we measured
peripheral blood neutrophil numbers at two hours as this was the time at which we assessed
glomerular neutrophil numbers. As shown in table I, no differences were seen between
groups in experiments with either IgG2a or IgG2b. Our findings regarding the role of
FcγRIII, FcγRI, FcγRIV and C3 in IgG2a or IgG2b-mediated disease could therefore not
be explained by differences in peripheral blood neutrophil numbers.
Discussion
The major finding in these studies is that IgG2a and IgG2b are the pathogenic IgG
subclasses in acute glomerular inflammation (IgG2a>IgG2b) and that IgG1 is not
pathogenic. Both FcγRIII and FcγRIV are required for neutrophil influx and glomerular
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damage mediated by IgG2a or IgG2b. We further demonstrated an additional role for
complement in proteinuria and thrombosis due to IgG2b but not IgG2a.
The relative potency of switch variants of IgG subclasses has been assessed in studies of
passively induced cellular depletion or cytotoxicity such as haemolytic anaemia (16, 27), B
cell depletion (18), thrombocytopenia and melanoma therapy (17). These studies agreed that
IgG2a and IgG2b were the most pathogenic in experimental situations where high affinity
antibodies are used. A recent further study documented that FcγRI, III and IV all
contributed to IgG2a mediated anaemia with FcγRIII and FcγRIV important for IgG2b-
mediated disease (28). Our study differs from these previous experiments in that we employ
switch variants to explore the role of IgG subclass in a model of tissue-specific immune-
complex mediated inflammation. This is the first such in vivo study.
A previous study in the heterologous nephrotoxic nephritis model has suggested an
important role for FcγRIII (29). Our experimental system is derived from this model, in
which acute glomerular inflammation is induced by a single dose of foreign polyclonal
antibody. Our finding of a dominant role for FcγRIII is consistent with this previous work,
and extends it by showing that FcγRIII is essential regardless of the IgG subclass initiating
disease. IgG1 is known to bind to FcγRIII, although with a lower affinity than IgG2a and
IgG2b (6). This lower affinity for FcγRIII may contribute to the lack of disease due to IgG1.
However a more convincing explanation is given by the additional requirement that we have
shown for FcγRIV which does not significantly bind to IgG1 (6). Our experiments did not
explore the contribution of binding to the inhibitory receptor FcγRIIb in this model. Recent
data have shown that pathogenicity is determined by the relative balance of interactions with
activating and inhibiting Fcγ receptors (17). IgG2b has a greater affinity than IgG2a for
FcγRIIb, and also a lower affinity for FcγRIV (6). These differences may explain the lesser
pathogenicity of IgG2b compared to IgG2a. IgG1 binds to FcγRIIb with higher affinity than
IgG2a and a similar affinity to IgG2b. This would also tip the balance towards a lack of
pathogenicity for IgG1.
There are at present limited in vivo data on the role of FcγRIV. In addition to the role in
IgG2a or IgG2b-mediated anaemia described above (28), FcγRIV blockade inhibited IgG2a
or IgG2b-mediated thrombocytopenia. In the anaemia study, the effect was seen in wildtype
mice only for IgG2b-mediated disease. For IgG2a-mediated disease, FcγRIV blockade only
had an effect in mice deficient in FcγRIII (28). In the thrombocytopenia studies the effect of
FcγRIV blockade was moderate and led to a partial inhibition of platelet reduction (6, 17).
FcγRIV is also important for tumour destruction though again the effect of FcγRIV
blockade was partial (17). The autologous phase of nephrotoxic nephritis is a model in
which progressive glomerulonephritis is mediated by a humoral and cellular immune
response to a foreign antibody planted on the glomerular basement membrane. One study
suggested a dominant role for FcγRIV in this model (30), though other studies have
supported a role for FcγRI and FcγRIII (31). This model is a different experimental system
from the current study however, and interactions of Fc receptors on both neutrophils and
macrophages may be important. In summary, previous data have shown a contribution of
FcγRIV to tissue injury, but in none has there been an absolute requirement for this
receptor, as shown in the experiments presented here. The requirement for both FcγRIII and
FcγRIV is similar to that seem when haemolytic anaemia is induced by IgG2b (28). This
suggests that in both of these experimental models, ligation of both of these receptors is
required in order to reach the threshold required for disease.
In the current work and these other studies, the role of FcγRIV has been explored using
blocking antibodies. It is unlikely that our data are complicated by an interaction of the Fc
portion of 9E9 with FcγRIII. Data in figure 8A shows no interaction of 9E9 with FcγRIII.
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In addition previous published work shows that 9E9 does not block IgG1 immune complex
activity and hence does not bind to FcγRIII in vivo (17). The current data extend the in vivo
role of FcγRIV to a model of neutrophil-mediated inflammation. They show a complete
requirement for FcγRIV in disease due to either IgG2a or IgG2b. A recent study concluded
that FcγRIII and FcγRIV both contributed to murine neutrophil activation by immobilised
immune complexes in vitro (32). A moderate effect was seen with deficiency or blockade of
one of these receptors, with complete abrogation of responses if both are deficient or
blocked. Our in vivo study is consistent with this in vitro work in showing a role for both
FcγRIII and FcγRIV. However it differs from the in vitro findings in showing that both
receptors are required, and that deficiency in either one is sufficient to prevent disease.
We also demonstrated a role for complement in IgG2b but not IgG2a mediated glomerular
damage. This is consistent with our immunofluorescence findings that IgG2b is a stronger
activator of the classical pathway than IgG2a. Complement activation due to different IgG
subclasses was assessed by immunofluorescence of frozen tissue sections. Glomerular C1q
staining was detectable at similar levels in mice given IgG2a and IgG2b following TNP-
conjugated nephrotoxic antibody. No deposition of C1q, C4 or C3 was seen in our study
after IgG1. In vitro studies have suggested that IgG1 does not activate complement, but have
not identified differences between the other subclasses (3, 4, 27). In the current study
however, we have shown a difference between IgG2b and IgG2a, with greater complement
activation for the former. We found similar fluorescence staining for C1q with IgG2a and
IgG2b, with greater C4 and C3 staining for IgG2b. This could suggest that both subclasses
bind C1q similarly, but that IgG2b is better able than IgG2a to activate C4 and the rest of the
classical pathway. However, immunofluorescence staining may not differentiate between
biologically important differences in C1q binding, and this must be interpreted with caution.
We found that IgG1 was not able to activate complement, as there was no glomerular C3 or
C4 deposition. This could have resulted from two possibilities. Firstly, IgG1 may have been
unable to bind C1q, and secondly, IgG1 may have been unable to activate the remainder of
the classical pathway after C1q binding. Our demonstration that C1q is not deposited in the
glomerulus with IgG1 shows that the first option is the case. It should be noted that recent
data has shown that C5 may be activated independently of C3 (33). This means that the lack
of effect due to C3 deficiency in IgG2a-mediated disease does not rule out the possibility of
a role for terminal complement components.
Previous work in the model of heterologous nephrotoxic nephritis has given conflicting
results on the role of complement in acute antibody-mediated glomerular inflammation. In
this model disease is induced by a single pathogenic dose of foreign nephrotoxic antibody.
Some studies have shown a role for complement in both neutrophil influx and proteinuria,
some a role in proteinuria but not neutrophil influx, and others a role in neither one nor the
other (34-37). The current data suggest a possible reason for these discrepancies. The
polyclonal antibodies used in these studies would have differed in subclass composition with
differing abilities to activate mouse complement and bind to mouse Fc receptors. We have
shown that complement activation may be required for proteinuria with some but not other
subclasses. In addition we did not show a role for complement in causing neutrophil influx
in any circumstances. However it is possible that with heterologous antibody that activates
complement well, but binds Fc receptors poorly, such an effect may occur. In the current
model and also in heterologous nephrotoxic nephritis, LPS is required as a cofactor with
antibody in order to induce disease. We have previously shown that stimulation of TLR4
(the LPS receptor) on both renal cells and leukocytes is required for disease induction in
heterologous nephrotoxic nephritis (38). The mechanism of the effects on neutrophils in
these models could include modulation of Fc receptor expression. Indeed previous data has
shown that both FcγRIII and FcγRIV are upregulated by LPS on myeloid cells (6) (39).
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In the model used in the current study, disease develops within hours of deposition of
antibody on the glomerular basement membrane, and is characterised by a glomerular
neutrophil influx. Therefore our findings concerning Fc receptors can be considered to apply
to neutrophil Fc receptors in the context of acute glomerular inflammation, and to reflect the
early stages of immune complex mediated glomerulonephritis. However in recent years, a
neutrophil glomerulitis has been recognised as a feature of humorally-mediated renal
transplant rejection (40). Although the antibodies in this context will be against HLA
molecules, the principles regarding the mechanisms by which antibody recruits and activates
neutrophils in the glomerulus may be similar. This will therefore widen the potential
relevance of our findings. In many forms of glomerular inflammation, humoral and cell-
mediated immunity combine to cause glomerular inflammation. We have isolated the
component due to humoral immunity in a simplified passive model in order to study in detail
IgG effector mechanisms. In an active immune response the processes we have described
will occur in parallel with cell-mediated mechanisms. It has been proposed that proliferative
crescentic glomerulunephritis is largely mediated by Th1 type immune responses, though
the relative roles of humoral and cell-mediated processes is not clear (41). In agreement with
this, we have shown that IgG2a and IgG2b subclasses, associated with Th1 type immune
response, are most pathogenic. It is likely that the immune complex-mediated acute
inflammation increases T cell recruitment to the glomerulus, and subsequent cell-mediated
processes. The manner in which humoral and cell-mediated processes interact in glomerular
and other inflammatory diseases is an area in need of further study.
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Figure 1.
Glomerular inflammation induced by switch variant monoclonal antibodies. A.
Immunofluorescence staining for trinitrophenol in mice given nephrotoxic antibody
conjugated with TNP. This shows a linear glomerular basement membrane pattern. B.
Immunofluorescence staining for mouse IgG in mice given anti-TNP monoclonal antibody
24 hours after an injection of TNP conjugated nephrotoxic antibody, again showing a linear
glomerular basement membrane pattern. C. Histological changes observed 2 hours after the
injection of anti-TNP monoclonal antibody given 24 hours after an intravenous injection of
TNP conjugated nephrotoxic antibody. This shows a prominent neutrophil influx (identified
as irregular lobulated nuclei). D. Endotoxin is required for the neutrophil influx. A
significant neutrophil influx is seen when both endotoxin (100ng) and 15mg/kg IgG2a anti-
TNP monoclonal are given together, but not when either is given alone. E. Switch variant
anti-TNP monoclonals have identical binding to TNP as shown by ELISA.
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Figure 2.
The relative pathogenicity of switch variant monoclonal antibodies. A. Numbers of
neutrophils infiltrating glomeruli at 2 hours in mice given the same intravenous dose of
switch variant anti-TNP monoclonal antibodies, with endotoxin 100ng, 24 hours after an
intravenous injection of TNP conjugated nephrotoxic antibody. The lps group are mice
given endotoxin 100ng alone in the second injection. Numbers for IgG2a were significantly
greater than for IgG2b, and numbers for IgG2b were significantly greater than for IgG1.
IgG1 did not cause a neutrophil influx above that seen with endotoxin alone. B. Even a
higher dose of IgG1 did not cause a neutrophil influx above that seen with endotoxin alone.
C. Albuminuria in the first 24 hours after anti-TNP monoclonal given with endotoxin 24
hours after an intravenous injection of TNP conjugated nephrotoxic antibody. IgG2a
induced a greater albuminuria than IgG2b. Even after a much higher dose of IgG1,
albuminuria was minimal. D. Quantitation of glomerular thrombosis, with results that mirror
those for albuminuria.
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Figure 3.
The relative pathogenicity of switch variant monoclonal antibodies. Histology after anti-
TNP monoclonal, given 24 hours after an intravenous injection of TNP conjugated
nephrotoxic antibody. The left hand column showns representative glomeruli 2 hours after
15mg/kg anti-TNP monoclonal antibody. Neutrophils are identified by lobulated nuclei,
with a greater number seen after IgG2a than IgG2b, and none shown after IgG1. The right
hand column shows representative glomeruli 24 hours after anti-TNP monoclonal antibody.
There is glomerular thrombosis after IgG2a, with less after IgG2b and none after IgG1.
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Figure 4.
Complement activation by switch variant monoclonal antibodies. A. Immunofluorescence
staining of glomeruli for C1q, C4 and C3 after 15mg/kg anti-TNP monoclonals with
endotoxin, or endotoxin alone (control), given 24 hours after an intravenous injection of
TNP conjugated nephrotoxic antibody. In the control group there was no C1q present, with
sparse mesangial C3 and prominent mesangial C4. After IgG2a or IgG2b linear capillary
wall C1q, C3 and C4 staining was present. In the case of C3 and C4, this was superimposed
on the mesangial staining, with more C3 and C4 after IgG2b. There was no C1q, C3 or C4
deposited after injection of IgG1 anti-TNP. B. Quantitative data confirming the above
findings.
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Figure 5.
Effector mechanisms of IgG2a induced disease. A. Numbers of neutrophils infiltrating
glomeruli 2 hours after IgG2a anti-TNP monoclonal with endotoxin, given 24 hours after an
intravenous injection of TNP conjugated nephrotoxic antibody. The WT control groups are
wildtype mice given endotoxin alone in the second injection. There were significantly less
neutrophils in FcγRIII -/- mice, with neutrophil numbers reduced to those seen after
endotoxin alone. There was no significant difference in neutrophil numbers for wildtype
compared to FcγRI -/- or C3-/- mice. B. Albuminuria in the first 24 hours after IgG2a with
endotoxin given 24 hours after an intravenous injection of TNP conjugated nephrotoxic
antibody. There was significantly less albuminuria in FcγRIII -/- mice compared to
wildtypes. There was no significant difference in albuminuria for wildtype compared to C3
-/- mice. C. Quantitation of the glomerular thrombosis, with results that mirror those for
albuminuria.
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Figure 6.
Effector mechanisms of IgG2b-induced disease. A. Numbers of neutrophils infiltrating
glomeruli 2 hours after IgG2b anti-TNP monoclonal with endotoxin given 24 hours after an
intravenous injection of TNP conjugated nephrotoxic antibody. The WT control groups are
wildtype mice given endotoxin alone in the second injection. There were significantly less
neutrophils in FcγRIII -/- mice, with neutrophil numbers reduced to those seen after
endotoxin alone. There was no significant difference in neutrophil numbers for wildtype
compared to FcγRI-/- or C3-/- mice. B. Albuminuria in the first 24 hours after IgG2b with
endotoxin was significantly less in FcγRIII-/- and C3-/- mice compared to wildtypes. C.
Quantitation of the glomerular thrombosis, with results that mirror those for albuminuria.
Giorgini et al. Page 17
J Immunol. Author manuscript; available in PMC 2009 June 15.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Figure 7.
The effect of combined FcγRI and C3 deficiency in IgG2a and IgG2b induced disease.
FcγRI-/-→C3-/- bone marrow chimeras were constructed and compared to WT→WT sham
chimera controls. A. Numbers of neutrophils infiltrating glomeruli 2 hours after IgG2a anti-
TNP monoclonal with endotoxin, given 24 hours after an intravenous injection of TNP
conjugated nephrotoxic antibody. The WT→WT control groups are WT→WT mice given
endotoxin alone in the second injection. There were no significant differences. B Shows a
similar experiment in which disease was induced by IgG2b anti-TNP.
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Figure 8.
Specificity of 9E9 and localisation of FcγRIV in diseased kidney. A. Characterisation of the
FcγRIV-specific monoclonal antibody 9E9. Chinese Hamster ovary cells were stably
transfected with the indicated Fc receptor (which was FLAG tagged). In the case of FcγRI,
FcγRIIII and FcγRIV the common γ chain was cotransfected. Shaded histograms are 9E9
staining and open histograms are isotype matched control antibody staining. Data showing
similar expression of all Fc receptors, using a FLAG-specific antibody, is in reference (6).
B. Immunofluorescence staining using 9E9 to show FcγRIV in inflamed kidney. A
representative section from a mouse in which a neutrophil influx was induced 2 hours
previously is shown. The arrow indicated a glomerulus (darker then the surrounding tubules)
with positive staining that is not seen in normal mice. The interstitium has some positive
cells which are also seen in normal mice.
Giorgini et al. Page 19
J Immunol. Author manuscript; available in PMC 2009 June 15.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Figure 9.
The role of FcγRIV in IgG2a and IgG2b induced disease. A. Numbers of neutrophils
infiltrating glomeruli 2 hours after IgG2a anti-TNP monoclonal with endotoxin, given 24
hours after an intravenous injection of TNP conjugated nephrotoxic antibody, and 90
minutes after 20mg/kg of anti-FcγRIV or control antibody. The control group (left group of
each graph) is wildtype mice given normal hamster IgG in the second injection and
endotoxin alone in the third injection. B. Shows a similar experiment in which disease was
induced by IgG2b anti-TNP. For both IgG2a and IgG2b induced disease, there were
significantly less neutrophils in mice given anti-FcγRIV antibody compared to control, with
neutrophil numbers reduced to those seen after endotoxin alone. C. Albuminuria in disease
induced by IgG2a with endotoxin, was significantly less after anti-FcγRIV compared to
control antibody. D. Albuminuria in disease induced by IgG2b with endotoxin was
significantly less after anti-FcγRIV compared to control antibody. E. Quantitation of the
glomerular thrombosis induced by IgG2a, with results that mirror those for albuminuria. F.
Thrombosis was also decreased by anti-FcγRIV antibody in IgG2b-induced disease.
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